Latest Deals

The deal includes a $175m upfront payment for Roivant’s subsidiary Dermavant. Credit: testing / Shutterstock

Organon is set to acquire Roivant’s immuno-dermatology subsidiary Dermavant in a potential $1.2bn deal. Organon will pay $175m upfront for the business as part of the transaction, which is expected to close in the fourth quarter of this year, as per an 18 September press release. Shares in both Organon and Roivant were down at close compared to their respective market opening prices on the day of the announcement. 

Novo Nordisk has signed a $600m deal with NanoVation to develop genetic medicines for rare and cardiometabolic diseases. Novo has secured a licence to use NanoVation’s long-circulating lipid nanoparticle (lcLNP) technology for RNA delivery targeting cells outside the liver. Both companies will collaborate on two programmes to develop base-editing therapies for rare genetic diseases, with plans for up to five future targets for cardiometabolic and rare diseases. 

UK-based startup Vicebio has raised $100m to advance its “next-generation vaccines” for respiratory illnesses, including respiratory syncytial virus (RSV) to Phase I trials. Vicebio is the latest biotech to eye up the RSV market, a space that has seen a buzz of development over the last year. Pharma giants GSK, Pfizer and Moderna have all brought vaccines for the illness to the market.

GC Therapeutics (GCTx) has propelled itself into the cell therapy space with $65m under its belt to deliver off-the-shelf induced pluripotent stem cell (iPSC)-based medicines. GCTx’s “plug and play” platform TFome – developed in the lab of Professor George Church at Harvard Medical School – transforms iPSCs into any cell type using a comprehensive collection of human transcription factors.